



Charles River Laboratories Announces Third-Quarter 2005 Results; Sales Reach \$274 million; GAAP Earnings Per Share of \$0.44 and \$0.57 on a Non-GAAP Basis; Company Updates Guidance for 2005

October 27, 2005

 [Downloadable version.](#)

Increases Stock Repurchase Authorization to \$100 Million

WILMINGTON, Mass., Oct 27, 2005 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE:CRL) today reported third-quarter 2005 financial results. Net sales for the third quarter of 2005 increased 55.6% to \$273.9 million, compared to \$176.0 million reported in the third quarter of 2004. The increase was due primarily to the acquisition of Inveresk Research Group, and also to continuing strong demand for outsourced preclinical services.

Net income on a GAAP basis was \$32.1 million, or \$0.44 per diluted share, in the third quarter of 2005, compared to \$25.8 million, or \$0.51 per diluted share, in the third quarter of 2004. On a non-GAAP basis, net income for the third quarter increased 61.5% to \$41.7 million, compared to \$25.8 million in the third quarter of 2004. Non-GAAP earnings per diluted share were \$0.57, compared to \$0.51 per diluted share in the third quarter of 2004, an increase of 11.8%. Non-GAAP results in the third quarter of 2005 exclude amortization of intangibles of \$13.2 million, or \$0.12 per diluted share, and compensation charges of \$1.3 million, or \$0.01 per diluted share, related to the acquisition of Inveresk.

James C. Foster, Chairman, President and Chief Executive Officer said, "Third-quarter sales of outsourced preclinical toxicology services and North American Research Models were strong, but overall growth was hampered by lower sales of large animals, lower demand for transgenic services in the United States and slower sales of interventional and surgical services, and of research models in Europe. Although sales growth was lower than we expected, our continuing focus on operating efficiency and the success of our integration efforts again allowed us to achieve excellent sequential operating margin improvement in the Preclinical and Clinical business segments. In addition, we are taking a number of actions in the fourth quarter that we expect will allow us to continue to improve operating efficiency, and expect to see the benefits of these actions in the fourth quarter and in 2006."

"We continue to believe that our extensive portfolio of value-added, essential products and services is extremely well positioned to benefit from the strong demand for drug discovery and development products and services, and are adding capacity and personnel to support our growth in the coming years," he said.

For the first nine months of 2005, net sales increased 57.1% to \$831.1 million from \$528.9 million for the same period in 2004. Net income on a GAAP basis was \$91.6 million, or \$1.28 per diluted share in the nine-month period in 2005, compared to \$69.7 million, or \$1.39 per diluted share, in the nine-month period in 2004. On a non-GAAP basis, net income for the year-to-date increased 62.7% to \$122.9 million, compared to \$75.5 million in the same period in 2004. Non-GAAP earnings per diluted share were \$1.70, compared to \$1.50 per diluted share in the same period in 2004. Non-GAAP results in the first nine months of 2005 exclude amortization of intangibles of \$39.7 million, or \$0.36 per diluted share, and compensation charges of \$7.1 million, or \$0.06 per diluted share, related to the acquisition of Inveresk. Non-GAAP results in the first nine months of 2004 exclude a net charge of \$5.8 million, or \$0.11 per diluted share, related to the write-off of a deferred tax asset and release of a related tax valuation allowance in connection with the Company's reorganization of its European operations.

Fourth-Quarter Actions

In order to improve overall operating efficiency, and particularly with respect to the Interventional and Surgical Services (ISS), Transgenic Services, and Clinical Services businesses, the Company will take a one-time, primarily non-cash charge in the fourth quarter of 2005 for impairment of fixed assets, intangible assets and lease obligations and for severance costs related to headcount reductions. The net effect of these charges is expected to be approximately \$0.09 per diluted share. The Company expects that these actions will result in improved margins in 2006.

The most significant of these actions will be the planned closure of Preclinical Services Wisconsin, one of the Company's two ISS facilities. The total ISS business, which is expected to report net sales in 2005 of approximately \$20 million, will be consolidated with the Company's Massachusetts location.

Also in the fourth quarter of 2005, the Company expects to repatriate up to \$150 million of its accumulated income earned outside the United States in a distribution that qualifies for the reduced tax rate under the American Jobs Creation Act of 2004. As a result of this repatriation, the Company expects that it will recognize a one-time net tax benefit conservatively estimated at \$15.0 million, or \$0.20 per diluted share.

The combined effect of these actions will be a one-time benefit in the fourth quarter of 2005 of at least \$0.11 per diluted share.

Business Segments Results

Research Models and Services

Third-quarter 2005 net sales for the Research Models and Services (RMS) segment of the business were \$118.9 million compared to \$118.1 million last year, an increase of 0.7%. Growth was due primarily to the North America Research Model and In Vitro Detection businesses, both of which achieved strong sales growth. This performance was partially offset by lower sales of large animal models; by the services businesses, particularly Transgenic Service sales in the United States; and by slower sales of research models in France. Primarily as a result of lower-than-expected sales in these businesses, and of higher fuel costs, the gross margin declined to 42.1% from 43.1% reported in the third quarter of last year and the operating margin was 30.9% compared to 32.2% in the same period last year.

Mr. Foster said, "Third-quarter growth in the RMS segment was lower than we expected, but we were very pleased by the 8.0% growth of North America research model production, which is the largest business in the segment, and the results of our In Vitro business. We believe that the issue affecting the large animal business is transitory and will be resolved in the near term, and the French business is expected to improve in the fourth quarter. Transgenic Services, which on an annual basis represents net sales of approximately \$55 million, will continue to be affected by our customers' shifting research focus from creation of transgenic models to characterization and validation of existing models. While this focus should benefit our model characterization business, it will continue to restrain the RMS segment's net sales growth. In order to mitigate the effect of lower sales, we have taken action in the fourth quarter to reduce headcount in Transgenic Services, which we expect will improve profitability in that business."

For the nine-month period, net sales were \$377.6 million, an increase of 5.6% from the \$357.7 million reported in the first nine months of 2004. The gross margin was 43.5% compared to 44.2% in the same period in 2004, and the operating margin was 32.3% compared to 32.9% in the nine-month period in 2004.

Preclinical Services

Net sales for the Preclinical Services segment were \$122.7 million in the third quarter of 2005, an increase of 111.7% from the \$57.9 million reported in the third quarter of 2004. The increase was due primarily to the acquisition of Inveresk, and to continuing strong demand for outsourced development services. Robust net sales of global toxicology services were partially offset by interventional and surgical services sales, which declined from the third quarter of 2004.

Mr. Foster added, "The demand for outsourced toxicology testing is very strong, and our sales in this area were robust. We are expanding capacity in most of our major locations to accommodate our customers' increasing demand. Combined with our continuing focus on instituting best practices and the consolidation of our Interventional and Surgical Services business and the resulting cost reductions, we expect to drive growth in Preclinical sales and profitability in the coming years."

As a result of strong sales growth, the segment's gross margin increased to 36.7% from 31.9% in the third quarter of 2004. Operating income was \$19.2 million in the third quarter of 2005, compared to \$9.8 million last year. The operating margin was 15.7% compared to 17.0% in the third quarter of 2004, with the decrease due primarily to amortization of intangibles related to the acquisition of Inveresk, offset in part by improved capacity utilization. On a non-GAAP basis, when excluding amortization of \$10.2 million related to the Inveresk acquisition, third-quarter operating income rose to \$29.5 million and the operating margin increased to 24.0%, reflecting higher sales and operating efficiencies.

For the first nine months of 2005, Preclinical net sales were \$355.8 million compared to \$171.2 million in the same period last year, an increase of 107.8%. The gross margin for the nine-month period rose to 35.4% from 32.1% in the same period last year, and the operating margin was 13.9% compared to 16.8% in the first nine months of 2004. On a non-GAAP basis, when excluding amortization of \$30.7 million related to the Inveresk acquisition, operating income for the first nine months of 2005 rose to \$80.2 million from \$28.8 million in the first nine months of last year and the operating margin increased to 22.5% from 16.8% in the same period last year.

Clinical Services

For the third quarter of 2005, net sales for the Clinical Services segment were \$32.4 million. The gross margin was 36.4%, operating income was \$3.1 million and the operating margin was 9.5%. On a non-GAAP basis, when excluding amortization of \$3.0 million related to the Inveresk acquisition, operating income was \$6.0 million and the operating margin was 18.7%.

Mr. Foster said, "We have continued to evaluate our Clinical Services business and as a result, determined that there are opportunities to streamline the business structure. We are reducing headcount in the administrative area to improve operating efficiency and believe that by doing so, we will support future margin expansion in this business."

For the first nine months of 2005, Clinical net sales were \$97.7 million and the gross margin was 33.5%. Operating income was \$5.9 million and the operating margin was 6.0%. On a non-GAAP basis, when excluding amortization of \$9.0 million related to the Inveresk acquisition, operating income was \$14.8 million and the operating margin was 15.2%.

Backlog

The backlog for Preclinical and Clinical Services at September 24, 2005, was \$431 million. The Company does not report backlog for the RMS business segment because turnaround time from placement to completion of orders, both for products and services, is rapid.

2005 Outlook

The following forward-looking guidance is based on current foreign exchange rates.

For the fourth quarter of 2005, the Company expects net sales to increase between 19% and 22%, and including the net benefit of one-time items, expects GAAP earnings per diluted share to be in a range of \$0.53 to \$0.55. Non-GAAP earnings per diluted share, which exclude acquisition-related amortization of intangible assets and compensation charges totaling \$0.14 per diluted share, and the one-time net benefit of approximately \$0.11 per diluted shares, are expected to be in a range of \$0.56 to \$0.58.

The Company now expects 2005 revenue growth in a range of 43% to 46% and GAAP earnings per diluted share in a range of \$1.81 to \$1.83. Non-GAAP earnings, which exclude acquisition-related amortization of intangible assets and compensation charges totaling \$0.56 per diluted share and the one-time net tax benefit of approximately \$0.11 per diluted share, are expected to be in a range of \$2.26 to \$2.28 per diluted share.

Board Increases Stock Repurchase Authorization

Charles River's Board of Directors has increased the existing authorization for the repurchase of Charles River common stock to \$100.0 million from the initial \$50.0 million authorization. The stock purchases will be made from time to time on the open market, through block trades or otherwise in compliance with Rule 10b-18 of the federal securities laws. Depending on market conditions and other factors, these repurchases may be commenced or suspended at any time or from time to time without prior notice. Funds for the repurchases are expected to come from cash on hand or cash generated by operations. As of October 21, 2005, the Company had repurchased 156,000 shares at a total cost of \$6.9 million. There are currently no

specific plans for the shares that have been or may be purchased under the program.

As of October 21, 2005, Charles River had approximately 72.3 million shares of common stock outstanding.

Webcast

Charles River Laboratories has scheduled a live webcast on Friday, October 28, at 8:30 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliation to comparable GAAP measures on the website. The webcast will be available until 5:00 p.m. ET on November 4, 2005.

Use of Non-GAAP Financial Measures

This press release contains non-GAAP financial measures which exclude, among other items, amortization of intangible assets and other charges related to the Inveresk acquisition. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. We believe that the inclusion of non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. Non-GAAP results also allow investors to compare the Company's operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in the text of, and the accompanying exhibits to, this press release, and can also be found on the Company's website at ir.criver.com.

Caution Concerning Forward-Looking Statements. This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding the future demand for drug discovery and development products and services; specific actions intended to improve overall operating efficiencies and profitability, particularly with respect to the Interventional and Surgical Services, Transgenic Services, and Clinical Services businesses; the Company's intention to repatriate cash in connection with the American Jobs Creation Act of 2004; and Charles River's future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to sales growth, efficiency improvements and operating synergies. Forward-looking statements are based on Charles River's current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: challenges arising from the acquisition and integration of Inveresk Research Group; a decrease in research and development spending or a decrease in the level of outsourced services; acquisition integration risks; the ability to convert backlog to sales; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on March 9, 2005, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.

About Charles River Laboratories

Charles River Laboratories, based in Wilmington, Massachusetts, is a global provider of solutions that advance the drug discovery and development process. Our leading-edge products and services are designed to enable our clients to bring drugs to market faster and more efficiently. Backed by our rigorous, best-in-class procedures and our proven data collection, analysis and reporting capabilities, our products and services are organized into three categories spanning every step of the drug development pipeline: Research Models and Services, Preclinical Services, and Clinical Services. Charles River's customer base includes all of the major pharmaceutical companies and many biotechnology companies, government agencies and leading hospitals and academic institutions. Charles River's 8,000 employees serve clients in more than 50 countries. For more information on Charles River, visit our website at www.criver.com.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(dollars in thousands, except for per share data)

	Three Months Ended		Nine Months Ended	
	September 24, 2005	September 25, 2004	September 24, 2005	September 25, 2004
Total net sales	\$ 273,938	\$ 176,026	\$ 831,073	\$ 528,856
Cost of products sold and services provided	167,145	106,629	507,883	316,010
Gross margin	106,793	69,397	323,190	212,846
Selling, general and administrative	42,978	24,821	135,445	82,161
Amortization of				

intangibles	14,321	1,202	43,002	3,591
Operating income	49,494	43,374	144,743	127,094
Interest income (expense)	(3,802)	(1,224)	(14,832)	(3,949)
Other, net	(493)	(83)	(977)	44
Income before income taxes and minority interests	45,199	42,067	128,934	123,189
Provision for income taxes	12,588	15,775	35,908	51,985
Income before minority interests	32,611	26,292	93,026	71,204
Minority interests	(538)	(471)	(1,445)	(1,489)
Net income	\$ 32,073	\$ 25,821	\$ 91,581	\$ 69,715
Earnings per common share				
Basic	\$ 0.45	\$ 0.56	\$ 1.33	\$ 1.51
Diluted	\$ 0.44	\$ 0.51	\$ 1.28	\$ 1.39
Weighted average number of common shares outstanding				
Basic	71,373,628	46,160,504	68,995,945	46,020,766
Diluted	73,372,960	52,552,617	72,942,571	52,395,604

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(dollars in thousands)

	September 25, 2005	December 25, 2004
Assets		
Current assets		
Cash and cash equivalents	\$ 167,705	\$ 207,566
Trade receivables, net	210,155	201,794
Inventories	65,021	61,914
Other current assets	55,886	39,032
Total current assets	498,767	510,306
Property, plant and equipment, net	386,310	357,149
Goodwill, net	1,418,179	1,422,586
Other intangibles, net	216,030	256,294
Deferred tax asset	44,395	50,412
Other assets	25,714	30,088
Total assets	\$2,589,395	\$2,626,835
Liabilities and Shareholders' Equity		
Current liabilities		
Current portion of long-term debt	\$ 80,256	\$ 80,456
Accounts payable	25,753	28,672
Accrued compensation	42,424	46,037
Deferred income	97,345	117,490
Other current liabilities	72,472	76,460
Total current liabilities	318,250	349,115

Long-term debt	297,363	605,388
Other long-term liabilities	178,493	190,035
	-----	-----
Total liabilities	794,106	1,144,538
	-----	-----
Minority interests	9,641	9,792
Total shareholders' equity	1,785,648	1,472,505
	-----	-----
Total liabilities and shareholders' equity	\$2,589,395	\$2,626,835
	=====	=====

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)

	Three Months Ended		Nine Months Ended	
	-----		-----	
	September	September	September	September
	24, 2005	25, 2004	24, 2005	25, 2004
Research Models and Services				
Net sales	\$118,882	\$118,089	\$377,565	\$357,651
Gross margin	50,020	50,897	164,361	157,945
Gross margin as a % of net sales	42.1%	43.1%	43.5%	44.2%
Operating income	36,713	38,043	122,071	117,835
Operating income as a % of net sales	30.9%	32.2%	32.3%	32.9%
Depreciation and amortization	5,024	4,507	14,800	13,112
Capital expenditures	5,584	6,970	17,375	15,365
Preclinical Services				
Net sales	\$122,661	\$ 57,937	\$355,840	\$171,205
Gross margin	44,970	18,500	126,120	54,901
Gross margin as a % of net sales	36.7%	31.9%	35.4%	32.1%
Operating income	19,245	9,836	49,478	28,807
Operating income as a % of net sales	15.7%	17.0%	13.9%	16.8%
Depreciation and amortization	16,491	3,572	50,080	10,500
Capital expenditures	40,023	3,274	52,222	6,746
Clinical Services				
Net sales	\$ 32,395	\$ -	\$ 97,668	\$ -
Gross margin	11,803	-	32,709	-
Gross margin as a % of net sales	36.4%	-	33.5%	-
Operating income	3,072	-	5,853	-
Operating income as a % of net sales	9.5%	-	6.0%	-
Depreciation and amortization	3,681	-	11,099	-
Capital expenditures	96	-	355	-
Unallocated Corporate Overhead \$ (9,536) \$ (4,505) \$(32,659) \$(19,548)				
Total				
Net sales	\$273,938	\$176,026	\$831,073	\$528,856
Gross margin	106,793	69,397	323,190	212,846
Gross margin as a % of net				

sales	39.0%	39.4%	38.9%	40.2%
Operating income	49,494	43,374	144,743	127,094
Operating income as a % of net sales	18.1%	24.6%	17.4%	24.0%
Depreciation and amortization	25,196	8,079	75,979	23,612
Capital expenditures	45,703	10,244	69,952	22,111

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)

	Three Months Ended		Nine Months Ended	
	September 24, 2005	September 25, 2004	September 24, 2005	September 25, 2004
Research Models and Services				
Net sales	\$118,882	\$118,089	\$377,565	\$357,651
Operating income	36,713	38,043	122,071	117,835
Operating income as a % of net sales	30.9%	32.2%	32.3%	32.9%
Preclinical Services				
Net sales	\$122,661	\$ 57,937	\$355,840	\$171,205
Operating income	19,245	9,836	49,478	28,807
Operating income as a % of net sales	15.7%	17.0%	13.9%	16.8%
Add back:				
Amortization related to acquisition	10,212	-	30,675	-
Operating income, excluding specified charges (Non-GAAP)	29,457	9,836	80,153	28,807
Non-GAAP operating income as a % of net sales	24.0%	17.0%	22.5%	16.8%
Clinical Services				
Net sales	\$ 32,395	\$ -	\$ 97,668	\$ -
Operating income	3,072	-	5,853	-
Operating income as a % of net sales	9.5%	-	6.0%	-
Add back:				
Amortization related to acquisition	2,972	-	8,986	-
Operating income, excluding specified charges (Non-GAAP)	6,044	-	14,839	-
Non-GAAP operating income as a % of net sales	18.7%		15.2%	
Unallocated Corporate Overhead	\$ (9,536)	\$ (4,505)	\$ (32,659)	\$ (19,548)
Add back:				
Stock-based compensation related to acquisition	1,313	-	7,107	-
Unallocated corporate overhead, excluding specified charges (Non-GAAP)	(8,223)	(4,505)	(25,552)	(19,548)

Total				
Net sales	\$273,938	\$176,026	\$831,073	\$528,856
Operating income	49,494	43,374	144,743	127,094
Operating income as a % of net sales	18.1%	24.6%	17.4%	24.0%
Add back:				
Amortization related to acquisition	13,184	-	39,661	-
Stock-based compensation related to acquisition	1,313	-	7,107	-

Operating income, excluding specified charges (Non-GAAP)	63,991	43,374	191,511	127,094
Non-GAAP operating income as a % of net sales	23.4%	24.6%	23.0%	24.0%

Charles River management believes that non-GAAP financial measures helps investors to gain a meaningful understanding of our core operating results and future prospects, consistent with the manner in which management measures and forecasts the Company's performance. The non-GAAP financial measures included are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS
(dollars in thousands, except for per share data)

	Three Months Ended		Nine Months Ended	
	September 24, 2005	September 25, 2004	September 24, 2005	September 25, 2004
Net income	\$ 32,073	\$ 25,821	\$ 91,581	\$ 69,715
Add back:				
Deferred tax asset write-off	-	-	-	7,900
Valuation allowance release	-	-	-	(2,111)
Amortization related to acquisition	13,184	-	39,661	-
Stock-based compensation related to acquisition	1,313	-	7,107	-
Tax effect	(4,873)	-	(15,485)	-

Net income, excluding specified charges (Non-GAAP)	\$ 41,697	\$ 25,821	\$ 122,864	\$ 75,504
=====				

Calculation of earnings per common share, excluding specified charges (Non-GAAP):

Net income for purposes of calculating earnings per share, excluding specified charges (Non-GAAP)	\$	41,697	\$	25,821	\$	122,864	\$	75,504
After-tax equivalent interest expense on 3.5% senior convertible debentures		-		1,012		1,463		3,035
		-----		-----		-----		-----
Income for purposes of calculating diluted earnings per share, excluding specified charges (Non-GAAP)	\$	41,697	\$	26,833	\$	124,327	\$	78,539
		=====		=====		=====		=====
Weighted average shares outstanding - Basic		71,373,628		46,160,504		68,995,945		46,020,766
Effect of dilutive securities:								
3.5% senior convertible debentures		-		4,759,455		1,987,465		4,759,455
Stock options and contingently issued restricted stock		1,677,113		1,293,848		1,623,966		1,277,632
Warrants		322,219		338,810		335,195		337,751
		-----		-----		-----		-----
Weighted average shares outstanding - Diluted		73,372,960		52,552,617		72,942,571		52,395,604
		=====		=====		=====		=====
Basic earnings per share	\$	0.45	\$	0.56	\$	1.33	\$	1.51
Diluted earnings per share	\$	0.44	\$	0.51	\$	1.28	\$	1.39
Basic earnings per share, excluding specified charges (Non-GAAP)	\$	0.58	\$	0.56	\$	1.78	\$	1.64
Diluted earnings per share, excluding specified charges (Non-GAAP)	\$	0.57	\$	0.51	\$	1.70	\$	1.50

Charles River management believes that non-GAAP financial measures helps investors to gain a meaningful understanding of our core operating results and future prospects, consistent with the manner in

which management measures and forecasts the Company's performance. The non-GAAP financial measures included are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP.

SOURCE: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.
Susan E. Hardy, 781-262-7616
Corporate Vice President, Investor Relations